In the Children’s Oncology Group cohort, however, outcomes in the DEK-NUP214 positive AML group were independent of FLT3-ITD, with no significant difference in the OS between the FLT3-ITD-positive and -negative groups (40% and 27%, respectively, p > 0.9) [107]. The gene discussed is NUP214; the disease is acute myeloid leukemia.